TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11887944

Group type: EXPERIMENTAL
Intervention: Nonionic contrast medium (iopromide)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Ionic contrast medium (diatrizoate sodium)
Number of subjects: 126
Study: 10193543

Group type: EXPERIMENTAL
Intervention: Continuous thermodilution (CCO) using Vigilance software version 4.35 and 4.39
Number of subjects: 56

Group type: COMPARATOR
Intervention: Iced bolus thermodilution (BCO)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Room temperature bolus thermodilution (BCO)
Number of subjects: 56
Study: 7763199

Group type: EXPERIMENTAL
Intervention: EPO (50-60 U/kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 9
Study: 2184488

Group type: EXPERIMENTAL
Intervention: Benzodiazepines (flurazepam 15 or 30 mg, triazolam 0.25 or 0.50 mg) and caffeine (250 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (for both benzodiazepines and caffeine)
Number of subjects: 80
Study: 7028356

Group type: EXPERIMENTAL
Intervention: Trimazosin (TMZ)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 26
Study: 30195561

Group type: EXPERIMENTAL
Intervention: Nonacidified liquid human milk fortifier
Number of subjects: 164

Group type: COMPARATOR
Intervention: Acidified liquid human milk fortifier
Number of subjects: 164
Study: 25452222

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Guided mastery therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Cognitive therapy and Guided mastery therapy
Number of subjects: 46
Study: 25105367

Group type: EXPERIMENTAL
Intervention: HIV-1 vaccine
Number of subjects: 0
Study: 22299661

Group type: EXPERIMENTAL
Intervention: Normal magnesium dialysate (1.8 mg/dL)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low magnesium dialysate (0.6 mg/dL)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Both groups (normal and low magnesium)
Number of subjects: 22
Study: 20584515

Group type: EXPERIMENTAL
Intervention: PREG-30 (30 mg/d)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: DHEA (400 mg/d)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: PREG-200 (200 mg/d)
Number of subjects: 58
Study: 17921407

Group type: EXPERIMENTAL
Intervention: Sunflower oil consumption with Thr54 variant
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Olive oil consumption
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Interaction between Ala54Thr polymorphism and type of oil consumed
Number of subjects: 1226
Study: 16350601

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH)
Number of subjects: 183

Group type: COMPARATOR
Intervention: atomoxetine
Number of subjects: 183
Study: 11986479

Group type: EXPERIMENTAL
Intervention: LSE + PT
Number of subjects: 81

Group type: COMPARATOR
Intervention: LSE-alone
Number of subjects: 81
Study: 9704715

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, epirubicin, and fluorouracil (CEF)
Number of subjects: 710

Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 710
Study: 8045968

Group type: EXPERIMENTAL
Intervention: Once daily biosynthetic GH (25 U/m2.week)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Twice daily biosynthetic GH (25 U/m2.week)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 2928987

Group type: EXPERIMENTAL
Intervention: Slow sodium (80 mmol/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sodium excretion
Number of subjects: 36
Study: 31380297

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 28592706

Group type: EXPERIMENTAL
Intervention: Long-acting pasireotide 20mg, 40mg, or 60mg
Number of subjects: 33
Study: 26144968

Group type: EXPERIMENTAL
Intervention: Citalopram (serotonin reuptake inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levodopa (dopamine precursor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citalopram and Levodopa
Number of subjects: 0
Study: 22940056

Group type: EXPERIMENTAL
Intervention: 1 dose of influenza vaccine
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 2 doses of influenza vaccine
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Vaccination ≥ 1 year post-transplantation
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Umbilical cord blood (UCB) recipients
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Total number of CD19(+) cells before vaccination
Number of subjects: 65
Study: 21943315

Group type: EXPERIMENTAL
Intervention: Telepsychiatry-based culturally sensitive collaborative treatment (T-CSCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 18495695

Group type: EXPERIMENTAL
Intervention: ehCG (5000 IU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rhCG (250 microg / 6500 IU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rhLH (150 IU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rhLH
Number of subjects: 0
Study: 17047615

Group type: EXPERIMENTAL
Intervention: 10 mg/day atorvastatin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 20 mg/day atorvastatin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both doses of atorvastatin
Number of subjects: 50
Study: 12714021

Group type: EXPERIMENTAL
Intervention: Dalteparin (120 IU/kg every 12h for 4-7 days)
Number of subjects: 439
Study: 10722441

Group type: EXPERIMENTAL
Intervention: Intravenous (iv) ceftriaxone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Penicillin G
Number of subjects: 30
Study: 8762788

Group type: EXPERIMENTAL
Intervention: One distal locking screw
Number of subjects: 44

Group type: COMPARATOR
Intervention: Two distal locking screws
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 8497018

Group type: EXPERIMENTAL
Intervention: Low-intensity warm-up (LWU) - 366-m swim at 70% VO2 max
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-intensity warm-up (HWU) - four 46-m swims at 1-min intervals at 110% VO2 max
Number of subjects: 10

Group type: COMPARATOR
Intervention: No warm-up (NWU)
Number of subjects: 10
Study: 3578255

Group type: EXPERIMENTAL
Intervention: Estrogen therapy (n = 53)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Orchidectomy (Control group)
Number of subjects: 100
Study: 31938843

Group type: EXPERIMENTAL
Intervention: Awareness of pediatric appropriate use criteria (AUC)
Number of subjects: 1079

Group type: EXPERIMENTAL
Intervention: Investigator chart review
Number of subjects: 1079

Group type: EXPERIMENTAL
Intervention: TTE findings in 'rarely appropriate' encounters
Number of subjects: 1079
Study: 29402628

Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA) with propofol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Volatile Induction and Maintenance of Anesthesia (VIMA) with sevoflurane
Number of subjects: 40
Study: 27692113

Group type: EXPERIMENTAL
Intervention: Allograft plus BMP-7 (OP-1)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Allograft alone
Number of subjects: 110
Study: 25730415

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion/alcohol
Number of subjects: 179

Group type: COMPARATOR
Intervention: Tryptophan depletion/placebo
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Tryptophan-balanced control/alcohol
Number of subjects: 179

Group type: COMPARATOR
Intervention: Tryptophan-balanced control/placebo
Number of subjects: 179
Study: 23735474

Group type: EXPERIMENTAL
Intervention: Rheolytic thrombectomy (RT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Manual thrombus aspiration (MTA)
Number of subjects: 80
Study: 21286008

Group type: EXPERIMENTAL
Intervention: GC501 trivalent inactivated influenza vaccine
Number of subjects: 329
Study: 19394473

Group type: EXPERIMENTAL
Intervention: Almond consumption (25 to 168 g/day)
Number of subjects: 142
Study: 16567606

Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg/d)
Number of subjects: 1252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1252
Study: 12756353

Group type: EXPERIMENTAL
Intervention: Chronic venous disease severity assessed by visual inspection (categories: normal, telangiectasias and spider veins, varicose veins, trophic changes)
Number of subjects: 2404

Group type: EXPERIMENTAL
Intervention: Chronic venous disease severity assessed by duplex ultrasound (categories: normal, superficial venous disease, deep vein disease)
Number of subjects: 2404

Group type: EXPERIMENTAL
Intervention: Functional scales of the SF-36
Number of subjects: 2404

Group type: EXPERIMENTAL
Intervention: Mental health scales of the SF-36
Number of subjects: 2404
Study: 11426633

Group type: EXPERIMENTAL
Intervention: CHOP plus INF (5Mu INF s.c. for 5 days on days 22 to 26 of each 28 day cycle, followed by INF 5 million units thrice weekly for 52 weeks for responders)
Number of subjects: 435

Group type: COMPARATOR
Intervention: CHOP alone
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: CHOP plus INF
Number of subjects: 435
Study: 9335522

Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere) - 3 cycles as neoadjuvant treatment
Number of subjects: 292

Group type: COMPARATOR
Intervention: No neoadjuvant chemotherapy
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Docetaxel and cisplatin - ongoing phase I/II dose escalation study
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Docetaxel and carboplatin - ongoing phase II nonrandomized trial
Number of subjects: 292
Study: 8442970

Group type: EXPERIMENTAL
Intervention: Clonidine with 15‐second laryngoscopy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clonidine with 45‐second laryngoscopy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo with 15‐second laryngoscopy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo with 45‐second laryngoscopy
Number of subjects: 40
Study: 3767347

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (1 g) plus probenecid
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cefuroxime axetil alone
Number of subjects: 36
Study: 29943702

Group type: EXPERIMENTAL
Intervention: Highest quartile of white blood cell on admission (cutoff points: >8.50×10^9/L)
Number of subjects: 3891

Group type: COMPARATOR
Intervention: Lowest quartile of white blood cell on admission (cutoff points: <5.60×10^9/L)
Number of subjects: 3891

Group type: EXPERIMENTAL
Intervention: Elevated white blood cell on admission
Number of subjects: 3891
Study: 26054823

Group type: EXPERIMENTAL
Intervention: Mechanical labor induction in obese women (BMI >30)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Mechanical labor induction in normal weight women (BMI ≤30)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Mechanical labor induction (general)
Number of subjects: 181
Study: 25356826

Group type: EXPERIMENTAL
Intervention: Eplerenone (50 mg bid for 8 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 22495111

Group type: EXPERIMENTAL
Intervention: Program of Cardiovascular Disease Prevention (PCVDP) implemented in active clinics
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no PCVDP)
Number of subjects: 66
Study: 19897857

Group type: EXPERIMENTAL
Intervention: CDB-2914 150 mg, in divided doses, administered over three consecutive days starting on Days 21, 49, and 77 after LNG-IUS insertion.
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo tablets administered over the same schedule as CDB-2914.
Number of subjects: 136
Study: 18604442

Group type: EXPERIMENTAL
Intervention: 30 mg/m2/week i.v. epirubicin for 8 weeks
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 30 mg/m2/week i.v. epirubicin for 8 weeks followed by monthly maintenance therapy for 4-6 months
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Oral estramustine phosphate (EMP) at a dose of 840 mg/day with weekly and monthly maintenance epirubicin
Number of subjects: 69
Study: 16000426

Group type: EXPERIMENTAL
Intervention: PCR analysis for pneumococci presence in middle ear effusions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional culture for pneumococci presence in middle ear effusions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molecular typing by amplified fragment length polymorphism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis of culture-negative effusions
Number of subjects: 0
Study: 12699416

Group type: EXPERIMENTAL
Intervention: Casein hydrolysed formula (Nutramigen)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Regular formula
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Autoantibody-positive children
Number of subjects: 103

Group type: COMPARATOR
Intervention: Autoantibody-negative children
Number of subjects: 103
Study: 10228814

Group type: EXPERIMENTAL
Intervention: Omeprazole plus amoxycillin plus tinidazole (OAT) for 2 weeks
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Omeprazole plus amoxycillin (OA) for 2 weeks
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Omeprazole plus clarithromycin plus tinidazole (OCT) for 1 week
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Omeprazole plus clarithromycin plus amoxycillin (OCA) for 1 week
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 200
Study: 8923867

Group type: EXPERIMENTAL
Intervention: GnRH agonist (leuprolide acetate, 500 micrograms, sc)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: hCG (5000 IU, im)
Number of subjects: 25
Study: 1296590

Group type: EXPERIMENTAL
Intervention: HAI of floxuridine (FUDR) 0.3 mg/kg/d for 14 days every 4 weeks
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (observation or systemic fluorouracil)
Number of subjects: 166
Study: 3904438

Group type: EXPERIMENTAL
Intervention: Isoxicam, 200 mg once a day
Number of subjects: 191

Group type: COMPARATOR
Intervention: Buffered aspirin, 3,600 mg per day (900 mg four times a day)
Number of subjects: 191
Study: 30947294

Group type: EXPERIMENTAL
Intervention: Predictive model developed using stepwise naïve and mixed-effect logistic regression.
Number of subjects: 5637

Group type: EXPERIMENTAL
Intervention: Data available in the scheduling system for model development.
Number of subjects: 5637

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 5637
Study: 30099762

Group type: EXPERIMENTAL
Intervention: split‐full‐split thickness flap elevation (test group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: split thickness approach (control group)
Number of subjects: 40
Study: 26309128

Group type: EXPERIMENTAL
Intervention: Discontinued oxytocin infusion
Number of subjects: 200

Group type: COMPARATOR
Intervention: Continued oxytocin infusion
Number of subjects: 200
Study: 25300266

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Light-intensity physical activity
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Maternal sedentary time
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Maternal physical activity
Number of subjects: 183
Study: 22030595

Group type: EXPERIMENTAL
Intervention: Self-controlled feedback
Number of subjects: 62

Group type: COMPARATOR
Intervention: Constant feedback
Number of subjects: 62
Study: 20382973

Group type: EXPERIMENTAL
Intervention: tramadol and a metal cannula
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: tramadol and a balloon catheter
Number of subjects: 128

Group type: COMPARATOR
Intervention: placebo and a metal cannula
Number of subjects: 128

Group type: COMPARATOR
Intervention: placebo and a balloon catheter
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: tramadol
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: balloon catheter
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: metal cannula
Number of subjects: 128
Study: 18596958

Group type: EXPERIMENTAL
Intervention: 60 microg YIC
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo (alum adjuvant)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: 30 microg YIC
Number of subjects: 242
Study: 16005708

Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy (DBT) for 52 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 58
Study: 12412676

Group type: EXPERIMENTAL
Intervention: Formoterol 4.5 microg
Number of subjects: 357

Group type: COMPARATOR
Intervention: Terbutaline 0.5 mg
Number of subjects: 357
Study: 10357919

Group type: EXPERIMENTAL
Intervention: Cell-free extracorporeal perfusion with hypertonic, hyperoncotic perfusate containing anti-oxidants (mean volume 1835 +/- 824 ml)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (surgical management: restorative procedure, thrombectomy or embolectomy)
Number of subjects: 35
Study: 8520059

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon-alpha cream (2 x 10(6) IU/g)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Podophyllotoxin cream (0.5%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 1744356

Group type: EXPERIMENTAL
Intervention: Albuterol, Cromolyn, Combination of Albuterol and Cromolyn
Number of subjects: 30

Group type: COMPARATOR
Intervention: None (Control Group II)
Number of subjects: 30

Group type: COMPARATOR
Intervention: None (Control Group I nonreactors)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: None (Group I reactors)
Number of subjects: 30
Study: 6336645

Group type: EXPERIMENTAL
Intervention: Glucagon hydrochloride 1 mg intravenously
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 14
Study: 30560738

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) for 16 weeks
Number of subjects: 104

Group type: COMPARATOR
Intervention: Antidepressant medication (ADM) for 16 weeks
Number of subjects: 104
Study: 29466592

Group type: EXPERIMENTAL
Intervention: Healthy Low-Fat (HLF) diet
Number of subjects: 609

Group type: COMPARATOR
Intervention: Healthy Low-Carbohydrate (HLC) diet
Number of subjects: 609

Group type: COMPARATOR
Intervention: Comparison between HLF and HLC diets
Number of subjects: 609

Group type: COMPARATOR
Intervention: Diet-genotype pattern interaction
Number of subjects: 609

Group type: COMPARATOR
Intervention: Diet-insulin secretion (INS-30) interaction
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 609
Study: 27197287

Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 1434

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 1434

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1434
Study: 25212929

Group type: EXPERIMENTAL
Intervention: Instructional video (group A, n = 20)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No intervention (group B, n = 22)
Number of subjects: 42
Study: 23148458

Group type: EXPERIMENTAL
Intervention: Video-based decision aid and researcher-led coaching session
Number of subjects: 128

Group type: COMPARATOR
Intervention: Highway safety video
Number of subjects: 128
Study: 19631473

Group type: EXPERIMENTAL
Intervention: Modified sham feeding (MSF)
Number of subjects: 13
Study: 17688076

Group type: EXPERIMENTAL
Intervention: Ranitab 150 mg film tablets (test preparation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 150 mg film tablets of the originator product (reference preparation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both test and reference preparations
Number of subjects: 0
Study: 16376753

Group type: EXPERIMENTAL
Intervention: Automated angle-independent motion tracking of mitral annular displacement (MAD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual tracing of endocardial borders for EF determination
Number of subjects: 0
Study: 12075259

Group type: EXPERIMENTAL
Intervention: Direct stenting without balloon predilation
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional stenting after balloon predilation
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional stenting
Number of subjects: 130
Study: 9584343

Group type: EXPERIMENTAL
Intervention: Articaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 20
Study: 7653829

Group type: EXPERIMENTAL
Intervention: Etomidate (0.15, 0.2, and 0.3 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Methohexital (0.75, 1.0, and 1.5 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propofol (0.75, 1.0, and 1.5 mg/kg)
Number of subjects: 10
Study: 2476426

Group type: EXPERIMENTAL
Intervention: 2 days of twice daily fractionation (370 cGy/fraction totaling 1480 cGy/course) for three courses (total dose 4440 cGy)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 2 days of twice daily fractionation (370 cGy/fraction totaling 1480 cGy/course)
Number of subjects: 142
Study: 1203889

Group type: EXPERIMENTAL
Intervention: cis-dichlorodiammineplatinum(II) alone
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: cis-dichlorodiammineplatinum(II) in combination with four other chemotherapeutic agents
Number of subjects: 178
Study: 31994309

Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil (BXM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baloxavir acid (BXA)
Number of subjects: 0
Study: 31473028

Group type: EXPERIMENTAL
Intervention: Childhood Asthma Control Test (C‐ACT)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group (no C‐ACT)
Number of subjects: 179
Study: 28007633

Group type: EXPERIMENTAL
Intervention: Active commuting
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Moderate intensity leisure time physical activity (LTPA)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Vigorous intensity leisure time physical activity (LTPA)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Sedentary controls
Number of subjects: 188
Study: 26417092

Group type: EXPERIMENTAL
Intervention: Placebo analgesia
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Opioid antagonist (naltrexone)
Number of subjects: 102
Study: 23690338

Group type: EXPERIMENTAL
Intervention: DRSP/EE-metformin
Number of subjects: 93

Group type: COMPARATOR
Intervention: DRSP/EE
Number of subjects: 93

Group type: COMPARATOR
Intervention: metformin
Number of subjects: 93